Robert Koch Institute (RKI) publishes stock-taking report on the current situation regarding Long COVID in adults

The Robert Koch Institute (RKI) has published a review on Long COVID in adults. To this end, the scientists analysed the international research literature on Long COVID published between January 2020 and June 2025. According to the review, about 10 to 15 percent of adults experience Long COVID symptoms in the 12-week period after infection with the SARS-COV-2 coronavirus. These include, among others, fatigue, concentration problems and shortness of breath. In addition to these Long COVID symptoms, other possible long-term health effects of COVID-19 include organ damage, worsening of pre-existing conditions or certain newly diagnosed illnesses.

The review also showed that women, unvaccinated individuals and people with pre-existing health conditions have a higher risk of developing Long COVID symptoms. About one in four to one in five of those affected report that their symptoms significantly limit their ability to perform daily activities. Furthermore, the literature review showed that in most affected individuals, Long COVID symptoms resolve within a year. However, in approximately 15 percent of those affected, the symptoms continue to persist beyond that period. The symptoms can significantly reduce the quality of life of those affected and drastically restrict their participation in everyday life.

The scientists emphasise that Long COVID is not only a burden for those affected and their families, but also continues to pose a major challenge to public health and the healthcare system. They highlight the need for further research into the causes and treatment options for Long COVID and other post-acute infection syndromes and of integrating the findings into the medical care provided to those affected.